Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $400.00

Alnylam Pharmaceuticals (NASDAQ:ALNY - Free Report) had its price objective increased by HC Wainwright from $395.00 to $400.00 in a report issued on Tuesday morning, Benzinga reports. They currently have a buy rating on the biopharmaceutical company's stock.

Other equities research analysts have also issued reports about the stock. Chardan Capital reiterated a buy rating and issued a $225.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday. JPMorgan Chase & Co. increased their target price on Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the company a neutral rating in a report on Thursday, February 1st. Royal Bank of Canada reissued an outperform rating and issued a $235.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 20th. Morgan Stanley decreased their price objective on Alnylam Pharmaceuticals from $184.00 to $176.00 and set an equal weight rating on the stock in a research note on Tuesday, February 13th. Finally, Wells Fargo & Company cut their target price on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an equal weight rating for the company in a research note on Friday, February 16th. Seven investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of Moderate Buy and a consensus target price of $216.19.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY traded up $3.11 on Tuesday, hitting $154.33. 353,436 shares of the company's stock were exchanged, compared to its average volume of 753,445. The firm's 50-day moving average price is $149.51 and its two-hundred day moving average price is $165.07. The firm has a market cap of $19.52 billion, a price-to-earnings ratio of -57.59 and a beta of 0.41. Alnylam Pharmaceuticals has a fifty-two week low of $141.98 and a fifty-two week high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating analysts' consensus estimates of ($0.75) by $0.23. The business had revenue of $494.33 million during the quarter, compared to analyst estimates of $428.01 million. During the same period last year, the business posted ($1.40) EPS. Alnylam Pharmaceuticals's revenue was up 54.8% compared to the same quarter last year. On average, research analysts predict that Alnylam Pharmaceuticals will post -4.43 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ALNY. Vanguard Group Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company's stock worth $2,286,181,000 after buying an additional 287,064 shares during the period. Wellington Management Group LLP grew its stake in Alnylam Pharmaceuticals by 6.0% during the 3rd quarter. Wellington Management Group LLP now owns 6,431,814 shares of the biopharmaceutical company's stock valued at $1,139,074,000 after acquiring an additional 364,021 shares in the last quarter. Capital International Investors increased its holdings in shares of Alnylam Pharmaceuticals by 15.8% in the 4th quarter. Capital International Investors now owns 3,586,657 shares of the biopharmaceutical company's stock valued at $686,641,000 after purchasing an additional 488,814 shares during the period. Capital Research Global Investors boosted its holdings in shares of Alnylam Pharmaceuticals by 5.3% during the fourth quarter. Capital Research Global Investors now owns 2,930,079 shares of the biopharmaceutical company's stock worth $560,880,000 after purchasing an additional 146,236 shares during the period. Finally, Norges Bank purchased a new position in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $390,438,000. 92.97% of the stock is owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.